Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Monopar Therapeutics Inc (NQ: MNPR )

5.840 +0.670 (+12.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 773,653
Open 5.440
Bid (Size) 5.820 (4)
Ask (Size) 5.890 (1)
Prev. Close 5.170
Today's Range 5.060 - 5.900
52wk Range 1.369 - 8.650
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Monopar Therapeutics (MNPR) Stock Is Skyrocketing Today
Monopar Therapeutics shares are trading higher by 108% Thursday morning. The company announced early Phase 1 trial data confirming MNPR-101-Zr's tumor-targeting ability in humans. 
Via Benzinga
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+215.68%
+215.68%
1 Month
+122.90%
+122.90%
3 Month
+56.67%
+56.67%
6 Month
+58.48%
+58.48%
1 Year
+102.15%
+102.15%

More News

Read More
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024
Via InvestorPlace
Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM’24
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Monopar and NorthStar Amend & Extend Collaboration
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely
Via InvestorPlace
Topics Regulatory Compliance
Exposures Legal Regulatory
Monopar Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Monopar Announces CFO Succession
From Monopar Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
From Monopar Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
From Monopar Therapeutics Inc.
Via GlobeNewswire
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
From Monopar Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.